On 28th November OxTalks will move to the new Halo platform and will become 'Oxford Events' (full details are available on the Staff Gateway).
There will be an OxTalks freeze beginning on Friday 14th November. This means you will need to publish any of your known events to OxTalks by then as there will be no facility to publish or edit events in that fortnight. During the freeze, all events will be migrated to the new Oxford Events site. It will still be possible to view events on OxTalks during this time.
If you have any questions, please contact halo@digital.ox.ac.uk
The Infectious Diseases Data Observatory (IDDO) will be hosting a webinar on the radical cure of P. vivax malaria and what we can do better on 3 February 2022 at 12pm GMT. Find out more and sign up here to join our one-hour research webinar with presentations and an expert discussion.
Two new studies using WWARN-hosted clinical trial data show that the dosing of the 8-aminoquinoline drugs primaquine and tafenoquine can be substantially improved. These analyses include the majority of all studied P. vivax malaria patients who received 8-aminoquinoline drugs over the last 20 years. Laboratory work confirms these findings and provides important new information on the mechanism of action of these essential medicines.
Speakers
· Dr Rob Commons, Menzies School of Health Research, on 8AQ efficacy in clinical trials
· Dr Alison Roth, Walter Reed Army Institute of Research, on laboratory studies assessing hypnozoitocidal activity
· Dr James Watson, Oxford University Clinical Research Unit, on the reassessment of tafenoquine pharmacometrics
· Discussion chaired by Dr Chau Nguyen Hoang, Oxford University Clinical Research Unit, and Professor Sir Nicholas White, Mahidol Oxford Research Unit
